INMUNE BIO INC (INMB) Stock Fundamental Analysis

NASDAQ:INMB • US45782T1051

1.36 USD
+0.03 (+2.26%)
Last: Mar 3, 2026, 12:34 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Taking everything into account, INMB scores 3 out of 10 in our fundamental rating. INMB was compared to 520 industry peers in the Biotechnology industry. INMB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. INMB is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • INMB had negative earnings in the past year.
  • In the past year INMB has reported a negative cash flow from operations.
  • INMB had negative earnings in each of the past 5 years.
  • INMB had a negative operating cash flow in each of the past 5 years.
INMB Yearly Net Income VS EBIT VS OCF VS FCFINMB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

  • With a Return On Assets value of -149.55%, INMB is not doing good in the industry: 84.04% of the companies in the same industry are doing better.
  • Looking at the Return On Equity, with a value of -196.58%, INMB is doing worse than 67.69% of the companies in the same industry.
Industry RankSector Rank
ROA -149.55%
ROE -196.58%
ROIC N/A
ROA(3y)-64.13%
ROA(5y)-50.5%
ROE(3y)-85.07%
ROE(5y)-64.85%
ROIC(3y)N/A
ROIC(5y)N/A
INMB Yearly ROA, ROE, ROICINMB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100

1.3 Margins

  • INMB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INMB Yearly Profit, Operating, Gross MarginsINMB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100K -200K -300K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • The number of shares outstanding for INMB has been increased compared to 1 year ago.
  • Compared to 5 years ago, INMB has more shares outstanding
  • There is no outstanding debt for INMB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
INMB Yearly Shares OutstandingINMB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
INMB Yearly Total Debt VS Total AssetsINMB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • INMB has an Altman-Z score of -8.50. This is a bad value and indicates that INMB is not financially healthy and even has some risk of bankruptcy.
  • INMB has a Altman-Z score of -8.50. This is in the lower half of the industry: INMB underperforms 69.04% of its industry peers.
  • There is no outstanding debt for INMB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.5
ROIC/WACCN/A
WACCN/A
INMB Yearly LT Debt VS Equity VS FCFINMB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

  • INMB has a Current Ratio of 4.17. This indicates that INMB is financially healthy and has no problem in meeting its short term obligations.
  • INMB has a Current ratio (4.17) which is comparable to the rest of the industry.
  • INMB has a Quick Ratio of 4.17. This indicates that INMB is financially healthy and has no problem in meeting its short term obligations.
  • With a Quick ratio value of 4.17, INMB perfoms like the industry average, outperforming 50.96% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.17
Quick Ratio 4.17
INMB Yearly Current Assets VS Current LiabilitesINMB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • INMB shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.75%.
  • The Revenue has grown by 19.05% in the past year. This is quite good.
  • Measured over the past years, INMB shows a very negative growth in Revenue. The Revenue has been decreasing by -57.31% on average per year.
EPS 1Y (TTM)2.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60%
Revenue 1Y (TTM)19.05%
Revenue growth 3Y-57.31%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • INMB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.00% yearly.
  • INMB is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 523.27% yearly.
EPS Next Y7.18%
EPS Next 2Y24.76%
EPS Next 3Y15.22%
EPS Next 5Y20%
Revenue Next Year376.19%
Revenue Next 2Y-41.42%
Revenue Next 3Y760.33%
Revenue Next 5Y523.27%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
INMB Yearly Revenue VS EstimatesINMB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M
INMB Yearly EPS VS EstimatesINMB Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 6

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • INMB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year INMB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INMB Price Earnings VS Forward Price EarningsINMB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INMB Per share dataINMB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

  • INMB's earnings are expected to grow with 15.22% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.76%
EPS Next 3Y15.22%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for INMB!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

INMUNE BIO INC

NASDAQ:INMB (3/3/2026, 12:34:49 PM)

1.36

+0.03 (+2.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-30
Earnings (Next)03-25
Inst Owners17.51%
Inst Owner Change3.66%
Ins Owners17.01%
Ins Owner Change0%
Market Cap36.16M
Revenue(TTM)50.00K
Net Income(TTM)-49.89M
Analysts80
Price Target5.36 (294.12%)
Short Float %18.4%
Short Ratio10.55
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-71.06%
Min EPS beat(2)-169.71%
Max EPS beat(2)27.6%
EPS beat(4)3
Avg EPS beat(4)-26.11%
Min EPS beat(4)-169.71%
Max EPS beat(4)27.6%
EPS beat(8)4
Avg EPS beat(8)-14.65%
EPS beat(12)6
Avg EPS beat(12)-146.22%
EPS beat(16)10
Avg EPS beat(16)-103.87%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-37.5%
EPS NQ rev (1m)-6.85%
EPS NQ rev (3m)10.34%
EPS NY rev (1m)0%
EPS NY rev (3m)-23.55%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 723.25
P/FCF N/A
P/OCF N/A
P/B 1.42
P/tB 1.42
EV/EBITDA N/A
EPS(TTM)-2.12
EYN/A
EPS(NY)-0.94
Fwd EYN/A
FCF(TTM)-1.2
FCFYN/A
OCF(TTM)-1.17
OCFYN/A
SpS0
BVpS0.95
TBVpS0.95
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -149.55%
ROE -196.58%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-64.13%
ROA(5y)-50.5%
ROE(3y)-85.07%
ROE(5y)-64.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.17
Quick Ratio 4.17
Altman-Z -8.5
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60%
EPS Next Y7.18%
EPS Next 2Y24.76%
EPS Next 3Y15.22%
EPS Next 5Y20%
Revenue 1Y (TTM)19.05%
Revenue growth 3Y-57.31%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year376.19%
Revenue Next 2Y-41.42%
Revenue Next 3Y760.33%
Revenue Next 5Y523.27%
EBIT growth 1Y15.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-123.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-117.08%
OCF growth 3YN/A
OCF growth 5YN/A

INMUNE BIO INC / INMB FAQ

What is the ChartMill fundamental rating of INMUNE BIO INC (INMB) stock?

ChartMill assigns a fundamental rating of 3 / 10 to INMB.


What is the valuation status of INMUNE BIO INC (INMB) stock?

ChartMill assigns a valuation rating of 0 / 10 to INMUNE BIO INC (INMB). This can be considered as Overvalued.


How profitable is INMUNE BIO INC (INMB) stock?

INMUNE BIO INC (INMB) has a profitability rating of 0 / 10.


How financially healthy is INMUNE BIO INC?

The financial health rating of INMUNE BIO INC (INMB) is 6 / 10.


What is the expected EPS growth for INMUNE BIO INC (INMB) stock?

The Earnings per Share (EPS) of INMUNE BIO INC (INMB) is expected to grow by 7.18% in the next year.